IP Verse

Combination Treatment Of Cancer - EP2785349

The patent EP2785349 was granted to Astrazeneca on Nov 9, 2022. The application was originally filed on Nov 30, 2012 under application number EP12795842A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2785349

ASTRAZENECA
Application Number
EP12795842A
Filing Date
Nov 30, 2012
Status
Patent Maintained As Amended
Oct 7, 2022
Grant Date
Nov 9, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TEVA PHARMACEUTICALSJul 14, 2020LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBBADMISSIBLE

Patent Citations (8) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0100172
DESCRIPTIONWO2006124118
DESCRIPTIONWO2009047563
DESCRIPTIONWO2010092371
DESCRIPTIONWO9320097
INTERNATIONAL-SEARCH-REPORTWO2009047563
INTERNATIONAL-SEARCH-REPORTWO2010092371
OPPOSITIONWO2009047563

Non-Patent Literature (NPL) Citations (11) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Christian Thomas, Et Al, "728 AZD5363, A NOVEL AKT INHIBITOR, DELAYS PROSTATE CANCER PROGRESSION", Journal of Urology, (20110516), pages e292 - e293, Journal of Urology, URL: https://www.auajournals.org/doi/10.1016/j.juro.2011.02.1697, (20210118), XP055766239-
OPPOSITION- C Thomas, Et Al, "UP02.098 The Novel AKT-Inhibitor AZD5363 Abrogates Androgen-Receptor Signaling and Delays Hormone-Sensitive and Castration-Resistant Prostate Cancer Progression in vivo", Urology, (20110901), page S293, XP055766244-
OPPOSITION- Francois Lamoureux, Et Al, "Abstract 4491: AZD5363, a novel Akt inhibitor, delays prostate cancer progression by inhibiting androgen-receptor activity", Proceedings: AACR 102nd Annual Meeting 2011, (20110401), pages 1 - 4, XP055766215-
OPPOSITION- Richard Luke, "Abstract 4478: Discovery of AZD5363, an orally bioavailable, potent ATP-competitive inhibitor of AKT kinases", Proceedings: AACR 102nd Annual Meeting 2011‐, (20110401), pages 1 - 4, XP055766223-
OPPOSITION- Thomas et al "Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo" Mol Cancer Ther, 2013,12(ll):2342-55-
OPPOSITION- Toren et al. "Combination AZD5363 with enzalutamide significantly delays enzalutamide resistant prostate cancer in preclinical models”, European Urology, 2015, 67(6), 986-990-
OPPOSITION- Brett Carver et al, "Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer", Cancer cell, Cell Press, (20110501), vol. 19, no. 5, doi:10.1016/j.ccr.2011.04.008, ISSN 15356108, pages 575 - 586, XP055039150
OPPOSITION- TimothyC. Thompson;, "Turning Reciprocal Feedback Regulation into Combination Therapy", CANCER CELL, CELL PRESS, US, US, vol. 19, no. 6, doi:10.1016/j.ccr.2011.05.022, ISSN 1535-6108, pages 697 - 699, XP028232331
OPPOSITION- Abhijit M. Godbole, Vincent C. O. Njar, "New Insights into the Androgen-Targeted Therapies and Epigenetic Therapies in Prostate Cancer", Prostate Cancer, (20110101), vol. 9, no. 3, doi:10.1155/2011/918707, ISSN 20903111, pages 347 - 13, XP055103247
OPPOSITION- B. R. Davies et al, "Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background", Molecular Cancer Therapeutics, American Association for Cancer Research, US, US, (20120401), vol. 11, no. 4, doi:10.1158/1535-7163.MCT-11-0824-T, ISSN 1535-7163, pages 873 - 887, XP055382504
OPPOSITION- R. J. Tallarida, "Quantitative Methods for Assessing Drug Synergism", Genes & Cancer, (20111101), vol. 2, no. 11, doi:10.1177/1947601912440575, ISSN 19476019, pages 1003 - 1008, XP055206103

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents